Pacira Pharma Revenue, Profits - PCRX Quarterly Income Statement

Add to My Stocks
$51.35 $3.5 (7.31%) PCRX stock closing price Sep 19, 2018 (Closing)

PCRX stock valuation based on fundamental analysis involves checking and analyzing financial statements and not just the Pacira Pharma stock price. In the income statement, an investor can check for important parameters like the topline or sales, the bottomline or profits, the basic EPS, dividends etc. The income statement is generated for a specific period of time, typically a year or a quarter. The revenue increase to $84.11M for 2018 Q2 impacts the PCRX stock. Investors typically check year over year or quarter over quarter revenue growth. The operating expenses as shown in the Pacira Pharma profit and loss statement for 2018 Q2 total to $56.65M. This line item shows that the operating expenses has decreased compared with last year. Also check: Pacira Pharma assets and Pacira Pharma free cash flow.

View and download details of revenue and profits for Pacira Pharma for latest & last 40 quarters.
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Pacira Pharma Revenues or Net Sales
Cost Of Goods Sold (COGS)20.92M22.88M21.3M18.22M23.81M24.58M23.63M43.15M23.05M20.27M
Pacira Pharma Gross Profit
Research & Development Expense12.24M14.37M10.04M11.77M18.85M16.63M17.07M9.75M9.36M9.49M
Selling General & Admin Expense44.41M44.28M39.3M40.9M44.04M42.12M34.69M36.31M43.66M37.95M
Income Before Depreciation Depletion Amortization6.54M-6.93M8.47M-3.57M-15.78M-14.05M-2.47M-20.86M-6.44M-2.25M
Depreciation Depletion Amortization----------
Non Operating Income1.46M1.44M1.27M1.14M1.29M-3.19M----
Interest Expense5.4M5.15M5.12M5.12M5.22M2.58M1.87M1.6M1.73M1.86M
Pacira Pharma Pretax Income
Provision for Income Taxes-------0.01M---
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations2.56M-10.68M4.6M-7.6M-19.74M-19.87M-3.97M-22.16M-7.96M-3.85M
Extraordinary Items & Discontinued Operations----------
Pacira Pharma Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS41.69M40.71M41.58M40.46M40.16M38M37.43M37.31M37.18M37.02M
Average Shares used to compute Basic EPS40.8M40.71M40.6M40.46M40.16M38M37.43M37.31M37.18M37.02M
Income Before Nonrecurring Items2.9M-7.48M7.77M-4.26M-11.78M-14.73M-4.17M---2.83M
Income from Nonrecurring Items-0.33M-3.2M-3.17M-3.34M-7.96M-5.13M--22.85M-8.21M-1.02M
Pacira Pharma Earnings Per Share Basic Net
Pacira Pharma Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items0.07-0.180.18-0.11-0.29-0.38-0.120.00-0.02-0.08
Preferred Dividends Acc Pd----------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

The key things to look for in an income statement while doing Pacira Pharma stock analysis are:

  • Revenue: The money received by selling of goods or services comes under this line item. A QoQ growth - See: Pacira Pharma revenue chart, implies that the company is growing. It has been the case with Pacira Pharma. One must look at stocks with increasing revenues, and stay away from stocks whose revenues or sales are declining.
  • Bottom line: Most businesses like Pacira Pharma try to grow their profits by growing their topline and by increasing their operating efficiency. A healthy bottom line growth implies a good investment.

The income statement is also called statement of revenue and expense. The PCRX financials along with Pacira Pharma historical stock prices provide a lot of details about the firm.

Pacira Pharma Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
Operating Margin
Net Profit Margin
Dividend Yield